These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34098075)

  • 21. HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.
    Emamaullee JA; Bral M; Meeberg G; Montano-Loza AJ; Bain VG; Burak KW; Bigam D; Shapiro AMJ; Kneteman N
    Can J Gastroenterol Hepatol; 2019; 2019():2509059. PubMed ID: 30775356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver transplantation for hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study.
    Khan AS; Adams N; Vachharajani N; Dageforde L; Wellen J; Shenoy S; Crippin JS; Doyle MB; Chapman WC
    Int J Surg; 2020 Mar; 75():84-90. PubMed ID: 32014598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
    Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
    Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study.
    Peschel G; Moleda L; Baier L; Selgrad M; Schmid S; Scherer MN; Müller M; Weigand K
    Transplant Proc; 2018 Jun; 50(5):1444-1450. PubMed ID: 29880368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression of fibrosis in liver transplant recipients with hepatitis C before and after sustained virologic response.
    Liu A; Angirekula M; Elhawary A; Mara K; Kulai T; Leise M; Watt KD
    Clin Transplant; 2023 Oct; 37(10):e15050. PubMed ID: 37329298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of kidney, liver, and simultaneous liver and kidney transplants from hepatitis c infected donors to hepatitis c naïve recipients: A large single center experience.
    Elbeshbeshy H; Modi N; Patel T; Matthews I; Kampert T; Lee J; Okeke R; Caliskan Y; Fleetwood V; Varma C; Gabris B; Bastani B; Abu Al Rub F; Guenette A; Befeler A; Agbim U; Desai R; Alsabbagh E; Qureshi K; Schnitzler M; Lentine KL; Randall HB; Nazzal M
    Clin Transplant; 2024 Jan; 38(1):e15161. PubMed ID: 37842872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
    Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
    Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
    Abdel-Wahab M; Abdel-Khalek EE; El-Gilany AH; Yassen AM; Al-Shobari M; Shiha U; Ali M; Sadani M; Salah T; Sultan AM; Elghawalby AN; Elmorshedi M; Al-Refaey AK; Abdalla U
    Arab J Gastroenterol; 2017 Sep; 18(3):151-155. PubMed ID: 28958486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.
    Kwong AJ; Wall A; Melcher M; Wang U; Ahmed A; Subramanian A; Kwo PY
    Am J Transplant; 2019 May; 19(5):1380-1387. PubMed ID: 30378723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excellent long-term patient and graft survival are possible with appropriate use of livers from deceased septuagenarian and octogenarian donors.
    Chedid MF; Rosen CB; Nyberg SL; Heimbach JK
    HPB (Oxford); 2014 Sep; 16(9):852-8. PubMed ID: 24467292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of antiviral treatment in hepatitis C virus liver transplant patients off immunosuppression in the direct acting antivirals era: A case series.
    Campos-Varela I; Agudelo EZ; Terrault NA
    Clin Transplant; 2018 Jul; 32(7):e13303. PubMed ID: 29851150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.